N-[6-(2,2-二甲基丙酰基氨基)吡啶-2-基]-2,2-二甲基丙酰胺 | 101630-94-8

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: N-[6-(2,2-二甲基丙酰基氨基)吡啶-2-基]-2,2-二甲基丙酰胺
• 英文名称: 2,6-bis(pivaloylamino)pyridine
• 英文别名: N,N'-(pyridine-2,6-diyl)bis(2,2-dimethylpropanamide)；N-[6-(2,2-Dimethyl-propionylamino)-pyridin-2-yl]-2,2-dimethyl-propionamide；N-[6-(2,2-dimethylpropanoylamino)pyridin-2-yl]-2,2-dimethylpropanamide
• CAS: 101630-94-8
• 化学式: C₁₅H₂₃N₃O₂
• 分子量: 277.367
• InChiKey: VPAGSMLGPQXYME-UHFFFAOYSA-N

物化性质

• 沸点：
  504.8±35.0 °C(Predicted)
• 密度：
  1.118±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  20
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  71.1
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 海关编码：
  2933399090
• WGK Germany：
  3
• 储存条件：
  室温

反应信息

• 作为反应物：
  描述：

  N-[6-(2,2-二甲基丙酰基氨基)吡啶-2-基]-2,2-二甲基丙酰胺 在 lithium hydroxide 作用下， 以 甲醇 为溶剂， 反应 1.0h， 以95%的产率得到2,6-二氨基烟醛
  参考文献：
  名称：

  Supramolecular Polymer Chemistry:  Self-Assembling Dendrimers Using the DDA·AAD (GC-like) Hydrogen Bonding Motif

  摘要：

  Heterocyclic unit 2 containing complementary donor-donor-acceptor (DDA) and acceptor-acceptor-donor (AAD) hydrogen bonding arrays at an angle of about 601 Was designed to self-assemble into a hexamer. To investigate whether this unit could self-assemble dendrimers, the 2,8-diamino-2-N-ethylpyrimido-(4,5-b)(1, 8)naphthyridine-3H-4-one subunit was synthesized with a first (2a), second (2b), and third generation (2c) Frechet-type dendron attached to the 8-amino group. The synthesis of 2a-c was accomplished in 11 steps beginning with 2,6-diaminopyridine and the corresponding dendron bromide. Studies using H-1 NMR, size exclusion chromatography (SEC), and dynamic light scattering (DLS) support the cooperative formation of cyclic hexamers in apolar solvents. The stability of the self-assembled dendrimers is dependent on the size of the attached dendron, and mixing studies with 2a-c indicate their usefulness in constructing dynamic combinatorial libraries.

  DOI：

  10.1021/ja0202006
• 作为产物：
  描述：

  2,6-二氨基吡啶 、 三甲基乙酰氯 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 21.0h， 以88%的产率得到N-[6-(2,2-二甲基丙酰基氨基)吡啶-2-基]-2,2-二甲基丙酰胺
  参考文献：
  名称：

  （杂）芳烃通过瞬态，非对称碘代烷的位点选择性CH功能化。

  摘要：

  已经开发了一种将芳烃和杂芳烃进行C-H官能化的策略，以允许位点选择性结合各种阴离子，包括Cl，Br，OMs，OTs和OTf。通过结合阴离子和稳定的PhI（OAc）2原位生成反应性，不对称碘化物，可以实现此方法。该机制的实用性通过与药用相关的芳烃的对位选择性氯化以及杂芳烃的位点选择性C–H氯化反应得以证明。光谱，计算和竞争实验描述了这些瞬态，不对称碘的独特性质，反应性和选择性。

  DOI：

  10.1016/j.chempr.2018.11.007

文献信息

• Imidazopyridine compounds as 5-HT4 receptor modulators
  申请人：——

  公开号：US20030092699A1

  公开（公告）日：2003-05-15

  This invention provides a compound of the formula (I): 1 or the pharmaceutically acceptable salts thereof wherein R 1 is hydrogen, halo or alkyl; R 2 and R 3 are independently hydrogen, alkyl, alkenyl, alkynyl, aminoalkyl or hydroxyalkyl; or R 2 and R 3 taken together with the nitrogen atom to which they are attached may form hetrocyclic; R 4 is hydrogen, halo, acyl, amino, amido, aryl, arylalkyl, or heteroaryl; R 5 is hydrogen, halo, alkyl, alkenyl, alkynyl, acyl, amino, amido, aryl, arylalkyl, or heteroaryl; R 6 is hydrogen, alkyl or alkoxyalkyl; X is NR 9 wherein R 9 is hydrogen or alkyl; and Y is (CR 7 R 8 ) n wherein n is an integer from 0 to 5. These compounds have 5-HT 4 receptor binding activity, and thus are useful for the treatment of gastroesophageal reflux disease, non-ulcer dyspepsia, Functional dyspepsia, irritable bowel syndrome or the like in mammalian, especially humans. This invention also provides a pharmaceutical composition comprising the above compound.

  这项发明提供了式(I)的化合物： 1 或其药学上可接受的盐，其中R 1 为氢、卤素或烷基；R 2 和R 3 独立地为氢、烷基、烯基、炔基、氨基烷基或羟基烷基；或R 2 和R 3 与它们连接的氮原子一起可能形成杂环；R 4 为氢、卤素、酰基、氨基、酰胺基、芳基、芳基烷基或杂芳基；R 5 为氢、卤素、烷基、烯基、炔基、酰基、氨基、酰胺基、芳基、芳基烷基或杂芳基；R 6 为氢、烷基或烷氧基烷基；X为NR 9 ，其中R 9 为氢或烷基；Y为(CR 7 R 8 ) n ，其中n为0至5的整数。 这些化合物具有5-HT 4 受体结合活性，因此对于哺乳动物，特别是人类的胃食管反流病、非溃疡性消化不良、功能性消化不良、肠易激综合征或类似疾病的治疗是有用的。该发明还提供了包含上述化合物的药物组合物。
• <i>N</i>-bromosuccinimide reactions of some heterocycles in the presence or absence of water: An overview of ring versus side chain bromination for the synthesis of important brominated heterocyclic synthons
  作者：Shyamaprosad Goswami、Kumaresh Ghosh、Reshmi Mukherjee、Avijit Kumar Adak、Ajit Kumar Mahapatra

  DOI：10.1002/jhet.5570380125

  日期：2001.1

  Reactions of various heterocycles 1–6 with N-bromosuccinimide in the presence or absence of water have been studied for side chain versus ring bromination to afford some new and important heterocyclic synthons. Interestingly, the N-bromosuccinimide reaction in the presence of perchloric acid, a new condition, affords exclusively the new dibromo aminopicoline 1f, which is not obtained by other presently

  对于侧链与环溴化反应，研究了各种杂环1-6与N-溴琥珀酰亚胺在有水或无水条件下的反应，以提供一些新的重要的杂环合成子。有趣的是，在高氯酸存在下的N-溴琥珀酰亚胺反应（一种新条件）仅提供了新的二溴氨基吡啶1f，这是目前其他研究方法无法获得的。
• [EN] N-SUBSTITUTED PIPERIDINYL-IMIDAZOPYRIDINE COMPOUNDS AS 5-HT4 RECEPTOR MODULATORS<br/>[FR] COMPOSES DE PIPERIDINYL-IMIDAZOPYRIDINE N-SUBSTITUES UTILISES COMME MODULATEURS DU RECEPTEUR 5-HT4
  申请人：PFIZER PHARMA

  公开号：WO2004026868A1

  公开（公告）日：2004-04-01

  This invention provides a compound of the formula (I): wherein Rl represents a hydrogen atom or a halogen atom; R2 represents a hydrogen atom, etc.; R3 represents an alkyl group having from 1 to 10 carbon atoms; said alkyl group in R3 is substituted by at least one substituent selected from the group consisting of substituents α ; said substituents α are selected from the group consisting of aryl groups, hydroxy groups, oxo groups, etc.; said aryl groups have 6 to 10 carbon atoms; said aryl groups are unsubstituted or substituted by at least one alkyl group having from 1 to 6 carbon atoms; said heterocyclic groups and heterocyclic moiety in heterocycliccarbonyl groups are 5- to 10-membered cyclic groups containing from 1 to 4 heteroatoms selected from the group consisting of nitrogen atoms, etc.; or a pharmaceutically acceptable amide of such compound, or a pharmaceutically acceptable ester of such compound, and pharmaceutically acceptable salts thereof. These compounds have 5-HT4 receptor binding activity, and thus are useful for the treatment of gastroesophageal reflux disease, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome or the like in mammalian, especially humans. This invention also provides a pharmaceutical composition comprising the above compound.

  这项发明提供了一个化合物的结构式(I)：其中R1代表氢原子或卤原子；R2代表氢原子，等等；R3代表具有1至10个碳原子的烷基基团；R3中的烷基基团被来自α取代基组的至少一个取代基所取代；所述α取代基选自芳基、羟基、酮基等组成的组；所述芳基含有6至10个碳原子；所述芳基未取代或被具有1至6个碳原子的至少一个烷基基团所取代；所述杂环基团和杂环基团中的杂环基在杂环羰基中是含有1至4个来自氮原子等组成的杂原子的5至10元环基团；或者是该化合物的药学上可接受的酰胺，或者是该化合物的药学上可接受的酯，以及其药学上可接受的盐。这些化合物具有5-HT4受体结合活性，因此对于哺乳动物，特别是人类的胃食管反流病、非溃疡性消化不良、功能性消化不良、肠易激综合征等的治疗是有用的。该发明还提供了包含上述化合物的药物组合物。
• A Direct Route to 3-(D-Ribofuranosyl)pyridine Nucleosides
  作者：Joseph A. Piccirilli、Tilman Krauch、Lawrence J. MacPherson、Steven A. Benner

  DOI：10.1002/hlca.19910740217

  日期：1991.3.13

  A route for synthesizing C-nucleosides with 2,6-substituted pyridines as heterocyclic aglycones is described. Condensation of appropriately substituted lithiated pyridines with ribono-1,4-lactone derivatives yields hemiacetal 4a–g (Table 1), which can be reduced by Et3SiH and BF3·Et2O to the corresponding C-nucleoside (see Scheme 1 for 4d β-D-5). Conditions are presented that optimize the amount of

  描述了用2，6-取代的吡啶作为杂环糖苷配基合成C-核苷的途径。适当取代的锂化吡啶与ribono-1,4-内酯衍生物的缩合产生半缩醛4a – g（表1），可通过Et 3 SiH和BF 3 ·Et 2 O还原为相应的C-核苷（参见方案1）对于4dβ-D- 5）。提出了优化形成的2，6-二氯吡啶衍生的β-D-异头物β-D- 5的量的条件（表3）。β-D- 5的酶解产生二氨基核苷14（方案3）。
• [EN] AMINO SUBSTITUTED PYRIDINYL METHANONE COMPOUNDS USEFUL IN TREATING KINASE DISORDERS<br/>[FR] COMPOSES DE PYRIDINYL-METHANONE AMINO SUBSTITUES UTILES DANS LE TRAITEMENT DE TROUBLES INDUITS PAR LA KINASE
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2005051387A1

  公开（公告）日：2005-06-09

  The present invention provides amino substituted pyridinyl methanone compounds; pharmaceutical compositions comprising the compounds and methods of synthesis thereof. The compounds, which are cyclin dependent kinase (CDK) inhibitors, can be used to treat or ameliorate CDK mediated disorders. The invention thus also provides the therapeutic or prophylactic use of the compounds and/or pharmaceutical compositions to treat such disorders.

  本发明提供了氨基取代的吡啶甲酮化合物；包括这些化合物的药物组合物以及它们的合成方法。这些化合物是细胞周期依赖性激酶（CDK）抑制剂，可用于治疗或缓解CDK介导的疾病。因此，本发明还提供了利用这些化合物和/或药物组合物治疗此类疾病的治疗或预防用途。